Health insurance & healthcare services

UnitedHealth Group

UNHDividend

The lower USD 330.48 regular close improves the entry price, while the CMS CRUSH proposal intensifies Medicare Advantage audit risk; UNH-specific exposure is unquantified and the proposal is not final. The source therefore raises attractiveness to 6.7/10 with a harsher adverse scenario, while business strength remains 7.2/10.

Analysis and ratings: ChatGPT·Business analysis 11/20/2026·Ratings & valuation 11/20/2026
THESIS STATUSRecovery supported · valuation is less forgiving
CONFIDENCEMedium in recovery durabilityHigh for reported results; medium for the durability of margin recovery.
HORIZON3–5 years
WHAT MATTERS MOSTCommercial pricing versus cost trend, reserves, Medicaid and OptumHealth’s margin path.

Business strength & price attractiveness

How AI assesses them

Business strength

Medium confidence
7.2/ 10

Previously 7.2 ·
Unchanged · Assessed

Business strength, independent of the stock price.

CRUSH raises regulatory uncertainty but is not final and UNH-specific exposure is unquantified. Without a new reported quarter, strength stays 7.2/10; price does not enter it.

Five areas & supporting evidence

Price Attractiveness

Medium confidence
6.7/ 10

Previously 5.5 ·
↑ +1.2 · Assessed

At 330.48 USD · close
Three-year horizon, through .

The lower USD 330.48 regular close improves the entry price, while the CMS CRUSH proposal intensifies Medicare Advantage audit risk; UNH-specific exposure is unquantified and the proposal is not final. The source therefore raises attractiveness to 6.7/10 with a harsher adverse scenario, while business strength remains 7.2/10.

Scenarios & supporting evidence

What changed in the latest update

New information: The lower USD 330.48 regular close improves the entry price, while the CMS CRUSH proposal intensifies Medicare Advantage audit risk; UNH-specific exposure is unquantified and the proposal is not final. The source therefore raises attractiveness to 6.7/10 with a harsher adverse scenario, while business strength remains 7.2/10.

Strength 7.2 → 7.2Attractiveness 5.5 → 6.7Scores changed

The numerical comparison does not by itself confirm or weaken the investment thesis.

Dated prices & model comparison
Input / modelPreviousCurrent
Reference price405.40 USD330.48 USD
Base modelled return+33.4 %+63.7 %
Adverse modelled return-33.3 %-31.4 %

Quote dates: 11/13/2026 → 11/19/2026. Model horizons end: 11/13/2029 → 11/20/2029. Cumulative returns include modelled dividends; they are scenarios, not guarantees.

View rating history →

Assessed · Methodology 1.2. Analytical judgments by ChatGPT; price changes do not automatically update these scores.

MARKET OVERVIEW

UNH · Price chart

Delayed data · English controls.TradingView
Analysis contents · 13 sections
01

Company Snapshot

UnitedHealth Group Incorporated — UNH | NYSE Sector: managed healthcare, care delivery, pharmacy services and healthcare technology Thesis status: Q3 results still support the operating recovery, while the November 16 CMS CRUSH proposal makes Medicare Advantage risk-adjustment exposure more concrete; commercial pricing, reserve quality and margin repair remain key tests Next quarterly results: date not searched yet — two full calendar months have not elapsed since the Q3 release on October 13, 2026, under methodology 1.2 Evidence confidence: high for reported figures and the regulatory proposal; medium for sustainable margin recovery and company-specific RADV exposure Valuation status: scenario framework Time horizon: three years

UnitedHealth combines UnitedHealthcare insurance with Optum healthcare services. The October 13 results and November 3 10-Q support the operating-repair thesis without establishing a return to historical growth. Since the last review, CMS has proposed materially stronger Medicare Advantage RADV recovery rules, including extrapolation from payment year 2018. The proposal is not final and CMS has not disclosed a UNH-specific amount, but it increases the range of regulatory and capital outcomes. Commercial cost trend above 11%, negative Medicaid margins, OptumHealth economics and reserve quality remain decisive.

Valuation quote: 330.48 USD, November 19, 2026 at 4:00 p.m. EST (10:00 p.m. Prague, CET), regular-session close, NYSE: UNH common stock. This is the latest completed regular-session quote used for valuation; all current scenarios use 330.48 USD. Quote · Price history

Scoring review November 20, 2026: Business strength 7.2/10; price attractiveness 6.7/10 at 330.48 USD, regular-session close dated November 19. Methodology 1.2, effective October 16, explicitly applied from the current Investment Analysis Rules. Company strength is unchanged: the CRUSH rule is proposed, company-specific exposure is unquantified and no new quarter has been reported. Price attractiveness rises from 5.5/10 because the quote fell 18.5%, partly offset by a more severe regulatory adverse case. Thesis status: operating recovery supported; regulatory risk materially higher.

02

Investment Thesis

  1. Pricing and portfolio repair continue to support earnings, but the commercial test is unfinished. Q3 adjusted EPS was $4.69 versus $2.92 a year earlier and 2026 adjusted EPS guidance is at least $20.50. On the October 13 call, management said commercial cost trend was still north of 11% and that 2027 pricing assumes elevated trend persists. This supports pricing discipline, while the longer path to target commercial margins keeps the thesis conditional.
  2. Optum provides several sources of earnings, but care delivery must earn its returns. Q3 OptumHealth adjusted operating profit was $588m and adjusted margin 2.6%. Management described Q4 risk seasonality and additional technology and clinician-workflow investment, with a 6–8% target margin path extending to 2028. Optum Rx reported management-claimed retention in the high 90s and external membership above half of covered lives, but did not disclose enough contract-level economics to prove that transparency changes preserve normalized profit.
  3. Recovery does not require medical inflation to disappear, but pricing must catch it. Management described commercial trend as stabilizing above 11%, Medicaid trend as moderating but still inadequately funded, and broad Medicare performance as better than expected. These are management statements, not separate reported segment margins. The base case requires 2027 pricing and state rates to close the gap without relying on recurring favorable reserve development.
  4. Returns depend on sustainable EPS and entry valuation. The current quote is about 19.8× the $20.50 adjusted EPS guidance floor. With unchanged analyst scenarios, the three-year base return is +33.4% including dividends and the adverse return −33.3%. The price therefore offers a conditional recovery return, with little cushion against slower margin repair.

Central debate: how much of the improvement represents durable pricing and operating repair, and how much reflects favorable claims development, seasonal conditions or contract mix? The new CMS CRUSH proposal adds a second question: whether retrospective RADV extrapolation from payment year 2018 creates a material recovery or capital burden for UNH. The proposal is not final, and the industry estimate cannot be assigned to UNH without company-specific audit evidence.

03

The Business

BusinessMain activityEconomic driver
UnitedHealthcareEmployer coverage, Medicare Advantage, Medicaid and other health benefitsPremiums and fees relative to medical and administrative costs
OptumHealthPrimary and specialist care, ambulatory services and home carePatient risk, contracted reimbursement, clinical outcomes and operating efficiency
Optum RxPharmacy benefit management and pharmacy servicesClient retention, service fees, purchasing arrangements and specialty pharmacy
Optum InsightHealthcare data, technology and administrative servicesClient implementations, product adoption and recurring service economics

UnitedHealthcare and Optum transact with each other. Their segment revenues overlap and must not be added together as consolidated revenue. Likewise, Optum businesses serving UnitedHealthcare are not wholly independent sources of demand.

For an insurer, a larger membership base is valuable only when reimbursement covers the associated risk. Exiting unattractive contracts can reduce revenue while improving earnings. For value-based care, the same principle applies: growth without adequate payment for patient complexity can destroy value.

04

Competitive Advantages

Scale and distribution. A broad insurance and care footprint supports relationships with employers, government programs, clinicians and pharmacy customers. Those relationships are difficult to reproduce quickly.

Operating information and integrated care. Claims, pharmacy and clinical capabilities can help identify avoidable utilization and coordinate treatment. Their value depends on accurate information, appropriate clinical decisions and measurable patient outcomes.

Established customer workflows. Insurance administration, pharmacy services and healthcare technology involve complex implementations. Reliable service can support retention, although customers can switch when pricing, access or performance disappoint.

Multiple routes to productivity. UNH can improve benefit design, care pathways, claims processing and administrative systems. Optum Insight can also commercialize useful internal capabilities.

These are analytical assessments of competitive position. Scale does not protect the group from mispricing medical risk, poor patient experiences or regulatory intervention. The 2025 deterioration demonstrates that an established franchise can still suffer a substantial earnings reset.

05

Growth Drivers

Margin recovery through repricing. Management says 2027 commercial pricing assumes cost trend remains elevated above 11%, while state Medicaid funding still trails medical costs. Medicare performance was described as better than expected. The investment case requires price and reimbursement adequacy to show up in reported margins across changing member mix.

OptumHealth operating repair. Q3 adjusted operating profit was $588m at a 2.6% adjusted margin. Management says core improvement is durable, but Q4 includes normal risk seasonality and extra technology and clinician-workflow investment. The stated 6–8% target margin is a 2028 objective, not 2027 guidance.

Pharmacy transparency and retention. Management said Optum Rx client retention is again in the high 90s and external customers now represent more than half of covered lives. Specialty volume grew 2.6% while overall quarterly volume declined 5%. These are useful demand indicators; undisclosed contract economics and regulatory change still determine whether retained volume converts into durable profit.

Healthcare automation. AI can reduce documentation and administrative work and support Optum Insight products. Management reported ambient documentation tools available to 70% of employed Optum providers, targeting more than 90% by year-end. Adoption is evidence of implementation; it is not a quantified group earnings contribution.

Capital allocation. Buybacks can support EPS as leverage improves. Long-term value still depends on the purchase price and the underlying business performance.

Sources for these management expectations and operational claims: Q3 2026 earnings-call transcript, October 13 and the preserved Q2 2026 transcript. The Q3 transcript is a third-party transcript of the official call. Management's 13–16% long-term EPS growth ambition and 2028 margin goals are objectives, not formal 2027 guidance.

06

Economics & Financial Profile

MetricLatest resultComparison / basis
RevenueQ3 2026: $112.694bn$113.161bn in Q3 2025
Operating earningsQ3: $6.563bn GAAP; $6.265bn adjustedGAAP $4.315bn a year earlier
Diluted EPSQ3: $4.56 GAAP; $4.69 adjusted$2.59 / $2.92 a year earlier
MCRQ3: 88.4%89.9% Q3 2025; 86.7% Q2 2026
Favorable medical reserve developmentQ3: $610mRelated to 2026 service dates
Operating cost ratioQ3: 12.8%13.5% a year earlier
Operating cash flowQ3: $5.1bn; 9M: $25.087bnTiming and regulated capital matter
Capital expenditure9M: $2.421bnProperty, equipment and capitalized software
Debt to capitalSept 30: 41.7%June 30: 41.2%; ~40% year-end objective
FY 2026 EPS outlookAt least $20.50 adjusted; $19.50 GAAPRaised October 13; July adjusted range $19.50–20.00
FY MCR outlookLast verified July: 88.1% ±25 bpsNo fresh numerical full-year range established from the Q3 release

Latest actuals and October guidance: official Q3 release, October 13, 2026, quarter and nine months ended September 30; Q3 10-Q, filed November 3; and Q3 call transcript, call held October 13. Reported figures, management claims and analyst scenarios are identified separately.

Earnings and reserve quality: Q3 included $610m of favorable medical reserve development related to 2026 service dates, about 0.7 percentage points of Q3 premium revenue; adding it back gives an illustrative 89.1% MCR versus 88.4% reported. Separately, the 10-Q reports $1.440bn of favorable prior-year medical-cost development for nine months, driven mainly by a favorable respiratory season, medical costs payable of $39.352bn and IBNR reserves of $26.7bn at September 30. These are distinct measures and should not be combined. Reserve-neutral progress remains the key quality test.

Seasonality: nine-month adjusted EPS of $18.30 leaves at least $2.20 for Q4 to reach the $20.50 floor, a residual calculation rather than standalone guidance. Management said OptumHealth Q3 operating improvement should continue, but Q4 reflects normal risk seasonality and additional investment. Business exits, patient risk, government-program mix and Optum Financial realignment affect comparisons; no quarter should be annualized.

Cash generation: nine-month operating cash flow was $25.087bn and purchases of property, equipment and capitalized software were $2.421bn, leaving a mechanical $22.666bn before acquisitions, investment purchases, insurance capital and other uses. The 10-Q attributes the year-on-year CFO increase partly to timing of government payments, working capital and pharmacy rebates. Only $1.2bn of $25.8bn cash and equivalents was available for general corporate use at September 30; operating cash is not the same as distributable parent cash.

Balance sheet, September 30: cash and short-term investments were $28.549bn; long-term investments $58.064bn; gross borrowings $74.331bn, calculated as $5.617bn current plus $68.714bn long-term debt. Debt/capital was 41.7%, with management still targeting approximately 40% by year-end. Insurance investments support policy obligations and required capital and are not all excess shareholder cash. Senior debt ratings carried negative outlooks at Moody's, S&P and Fitch in the 10-Q.

07

Key KPIs

KPILatest evidenceMonitor
MCR and reservesQ3 MCR 88.4%; $610m favorable current-service development; 9M prior-year development $1.440bn; payable $39.352bnReserve-neutral progression, pricing versus claims and Q4 seasonality
Medicare Advantage and StarsAt least 69% in 4+ Star plans in the release; management expects to approach 75% for payment year 20282028 bonus economics, member mix and cost of quality investment
RADV and regulationCMS proposed no FFS adjuster, CMS-set sampling and extrapolation beginning with payment year 2018; CMS estimates about $9bn per payment year in industrywide MA recoveriesFinal rule, litigation, audit sampling and any UNH-specific exposure or capital effect
CommercialManagement says cost trend remains above 11% but is stabilizing; 2027 pricing assumes persistenceReported margin recovery, affordability and risk/fee mix
MedicaidManagement says margins remain negative and 2026 is moderately better than its forecast rangeState rate adequacy; management aspires to target margins by end-2028
OptumHealthQ3 adjusted profit $588m; adjusted margin 2.6%Q4 risk seasonality and progress toward 6–8% target by 2028
Optum RxRetention high 90s; more than 50% of covered lives external; specialty volume +2.6%Transparent-fee economics, retention and profit per contract
Cash, shares and leverage9M CFO $25.087bn; 896m shares outstanding; debt/capital 41.7%Government-payment timing, capex, regulated capital, regulatory recoveries and net buybacks after SBC

Sources: Q3 release, October 13; Q3 call transcript, October 13; and Q3 10-Q, filed November 3. Separate commercial and Medicaid margins were not reported; statements about trend, retention and target timing are management claims.

CMS, October 8: 2027 Star Ratings affect 2028 quality-bonus payments. UNH's release said at least 69% of members were in 4+ Star plans; on the call management said it expects to approach 75% for payment year 2028 versus about 70% for the industry. The latter is an expectation, not a reported payment outcome, and the dollar effect remains unquantified.

08

Management & Capital Allocation

Stephen Hemsley's leadership is focused on operating discipline, portfolio simplification and restoring reliable performance. Tim Noel leads UnitedHealthcare, Patrick Conway leads Optum and Wayne DeVeydt is CFO. The relevant credibility test is delivery against medical-cost assumptions and earnings guidance across several quarters.

Buybacks and leverage: nine-month repurchases were $5.031bn, covering about 13.8m shares at an average $359.55; shares outstanding fell from 906m at year-end to 896m at September 30. Nine-month SBC expense was $843m, so gross buybacks are not net dilution. In November the board authorized up to 50m additional shares, but authorization is not a funded forecast. Debt/capital of 41.7% and regulated capital needs remain ahead of discretionary repurchases in the scenario assumptions.

Dividend profile: the board declared another $2.32 quarterly dividend on November 4, payable December 15 to holders of record December 7. The annualized rate is $9.28. At 330.48 USD, indicated yield is 2.81% and payout against the $20.50 adjusted EPS guidance floor is 45.3%. Future dividends remain discretionary, and the EPS ratio alone does not prove parent-cash coverage. November 4 declaration

UNH therefore fits a recovery and dividend-growth analysis better than a high-current-income analysis. Investment spending and acquisitions should be judged alongside debt reduction, cash available at the parent and returns on the existing portfolio.

09

Risks / Bear Case

  • Medical costs outpace pricing. Elevated utilization, provider billing intensity, specialty drugs and reimbursement gaps can overwhelm otherwise sound execution. Commercial costs already exceed the original assumption.
  • The recovery depends too heavily on favorable development. Earnings could weaken when claims estimates normalize or assumptions prove optimistic.
  • OptumHealth takes inadequately compensated risk. More patients do not create value if payments fail to reflect their complexity or care costs.
  • Regulation changes the economics. Medicare funding, risk adjustment, Star Ratings, Medicaid reimbursement and PBM rules can alter revenue and margins.
  • Care-access failures damage the franchise. Patient and provider dissatisfaction can lead to customer losses, remediation costs and more restrictive oversight.
  • Cybersecurity and system failures recur. Disruption can affect patients, provider payments, technology customers and cash collection.
  • Recovery takes longer than the valuation allows. EPS can disappoint while investors also reduce the multiple.

Current regulatory evidence: on November 16 CMS issued the proposed CRUSH rule. For Medicare Advantage RADV audits it would codify no fee-for-service adjuster, let CMS determine sampling and extrapolate findings beginning with payment year 2018; CMS estimates about $9bn per payment year of MA overpayment recoveries across the industry. The proposal was published November 19 and comments are due January 19, 2027. It is not final, and neither CMS nor UNH has disclosed a UNH-specific liability. The Q3 10-Q already identifies risk-adjustment coding and RADV audits as unresolved. The proposal therefore widens the downside range but is not treated as a booked charge. CMS fact sheet · Federal Register proposal

The downside mechanism combines weaker underwriting, slower Optum recovery and a lower valuation multiple. The integrated structure can amplify shared pressures as well as provide opportunities to improve care.

10

Valuation

ChatGPT produces the calculations and valuation scenarios. Share-price inputs are dated to the analysis; they are not continuously updated market data.

CHATGPT SCENARIOS · 20. 11. 2026 → 20. 11. 2029

Different outcomes. Different values.

Historical analysis input
330.48 USD · 19. 11. 2026 · 16:00 EST / 22:00 CET
Adverse
208 USD
Base
513 USD
Conditional scenarios from the analysis. The dashed line marks the historical share price used in the calculation. Values are neither current intrinsic value nor a share-price forecast.

Current valuation basis: 330.48 USD, regular-session close on November 19 at 4:00 p.m. EST. The November 13 pre-market basis of 405.40 USD, the October 13 basis of 384.19 USD and earlier prices are historical and preserved in the review history, not used for current returns. Quote

Earnings basisEPSP/E at 330.48 USD
FY 2026 management adjusted guidance floor, Oct 13At least $20.5016.1× at the floor
FY 2026 management GAAP guidance floor, Oct 13At least $19.5016.9× at the floor
Historical adjusted consensus FY 2026, Oct 8$19.8716.6×; pre-results estimate, not current consensus
Historical adjusted consensus FY 2027, Oct 8$22.6114.6×; pre-results estimate, not current consensus

Current guidance: October 13 Q3 release. Historical consensus retained from Stock Analysis, October 8 snapshot in the prior analysis; it is not represented as a newly updated estimate. FY 2027 consensus is not company guidance. P/E is calculated; stronger EPS than the floor would reduce the multiple.

Preferred method: normalized diluted EPS, checked against cash generation, reserve quality and capital needs. Q3 diluted weighted-average shares were 902m; this EPS denominator is not the current outstanding share count. Q3 financial schedules

A mechanical enterprise-value calculation that subtracts all insurance investments would misstate distributable capital. The scenarios below use equity EPS, with interest expense already included, and do not add a separate cash value.

Illustrative Three Year Scenarios

Analyst assumptions for FY 2029, approximately three years to November 2029. Future prices are not present fair values, consensus or formal company targets. Base and adverse cases use the same current quote and horizon as the detailed score section.

ScenarioFY 2029 adjusted EPSP/EFuture pricePrice-only return from 330.48 USD
Adverse$16.0013×$208−37.1%
Base$27.0019×$513+55.2%
Bull, supplemental$30.5022×$671+103.0%

Adverse: medical inflation and underpricing suppress commercial and Medicaid margins, OptumHealth stalls, and the CRUSH rule is finalized substantially as proposed with a meaningful UNH recovery and capital burden. $16 EPS represents approximately −7.9% annual change from the $20.50 guidance floor; 13× reflects persistent regulatory and execution risk. A larger company-specific RADV exposure can produce worse outcomes.

Base: pricing repair continues gradually and the final RADV framework or UNH-specific audit outcome remains manageable. Adjusted EPS of $27 requires approximately 9.6% annual growth from $20.50. The terminal 19× multiple requires a re-rating from the current 16.1× guidance-floor multiple. No new reported quarter justifies raising the FY 2029 EPS assumption.

Bull: $30.50 EPS requires about 14.2% annual growth from $20.50 and a 22× multiple. Better margins, productivity and confidence than the base case are necessary. This supplemental case does not drive the price score.

Future price = EPS × P/E; price-only return = future price ÷ 330.48 − 1. This table excludes dividends; the detailed two-case assessment includes them and is authoritative for the price score. Future prices are undiscounted; no probabilities assigned.

Valuation judgment: the lower quote creates meaningful upside if operating repair compounds, but the new RADV proposal makes the adverse tail wider and more concrete. The base present-value check is 23.6% above the quote, while the revised adverse case still loses about 31% including dividends. A lower share price improves expected return; it does not resolve underwriting, capital or regulatory risk.

11

What Would Change the Assessment?

These are analytical monitoring rules, not management guidance or automated trading instructions.

ObservationEffect on the thesis
Full-year MCR exceeds the July guidance range without a convincing explanationWeakens confidence in underwriting and cost forecasting
Commercial pricing repeatedly fails to catch medical inflationExtends the recovery and lowers sustainable EPS assumptions
OptumHealth comparable profitability deteriorates after allowing for stated seasonalityChallenges the operating-repair thesis
Favorable development repeatedly supplies most of earnings improvementReduces confidence in underlying growth
Final RADV rules, audits or litigation quantify a material UNH recoveryReassess normalized earnings, capital, dividends and the valuation multiple
Star Ratings materially reduce expected 2028 economicsRequires a fresh earnings and valuation assessment
Operating repair continues while leverage falls and cash supports distributionsStrengthens confidence in a durable recovery

Quarterly comparisons must account for business exits, changes in patient mix, adjustments and the timing of claims. In particular, Q3 and Q4 need to be assessed against the explicitly weaker second-half earnings cadence.

12

Current View

Business strength

Business strength: 7.2/10. Assessed: November 20, 2026. Methodology: 1.2. Five areas, equal 20% weights, independent of share price, under the current Investment Analysis Rules. Component judgments are whole points; only the arithmetic average is shown to one decimal place.

AreaScoreMain evidence
Competitive advantage8/10Established distribution and integrated insurance, care and pharmacy capabilities; high Optum Rx retention supports embedded workflows, while scale brings concentrated MA regulatory exposure.
Durability of demand9/10Essential healthcare demand persists; portfolio exits change profitable volume rather than the need for care. Government reimbursement remains a constraint.
Management execution6/10Q3 beat, higher guidance and clearer pricing discipline support execution. Commercial trend remains above 11%, Medicaid margins negative and the company-specific RADV response is not yet quantified.
Business economics6/10Better Q3 profitability and OptumHealth progress are offset by material reserve development, incomplete commercial repricing, a 2.6% adjusted OptumHealth margin and wider regulatory downside.
Financial resilience7/10Strong operating cash and a lower share count help; only $1.2bn cash was available for general corporate use, debt/capital was 41.7% and insurer capital is constrained.

Calculation: (8 + 9 + 6 + 6 + 7) ÷ 5 = 7.2/10, rounding only the final average. All five whole-point component judgments retain their prior levels. The share-price fall does not enter company strength.

  • Rationale: no additional reported quarter has been released. The CRUSH proposal materially raises regulatory uncertainty, but it is not final and UNH-specific exposure is unquantified; that is insufficient by itself to change a whole-point component. Commercial trend above 11%, negative Medicaid margins, reserve dependence and capital constraints keep the score unchanged.
  • Main weakness: medical costs can outpace premiums and risk-based reimbursement, weakening both insurance and OptumHealth economics at the same time. Scale cannot remove that risk.
  • Confidence: medium. Reported results and the CMS proposal are verified, but the durability of margin repair, the final rule and UNH-specific RADV outcomes remain uncertain.
  • Condition for change: raise execution/economics after another comparable reported quarter confirms recovery through seasonality, adequate commercial pricing, Medicaid improvement and progress beyond favorable reserve development. Reduce relevant components if a final RADV rule or audit creates a material recurring earnings or capital burden, or after cost-driven guidance cuts, renewed OptumHealth deterioration or capital stress.

Price Attractiveness

Price attractiveness: 6.7/10 at 330.48 USD. Quote: November 19, 2026, 4:00 p.m. EST, regular-session close. Assessed: November 20, 2026. Horizon: three years to November 2029. Methodology: 1.2. Security: UnitedHealth Group Incorporated common stock, NYSE: UNH. Market quote.

Current P/E is 16.1× the $20.50 management adjusted EPS floor. The base remains $27 at 19×; the adverse case is revised from $18 at 14× to $16 at 13× to reflect a plausible final RADV rule and regulatory de-rating. At 330.48 USD the cases yield +63.7% / −31.4% including dividends. The lower quote improves entry economics, while the harsher adverse case prevents a mechanical move to the prior 7.0 trigger.

ItemBase caseAdverse case
Business and marginsAdequate 2027 pricing gradually restores commercial and Medicaid economics; Medicare remains profitable; OptumHealth progresses toward 6–8% by 2028. The final RADV framework or UNH-specific outcome remains manageable. FY 2029 adjusted EPS $27, ~9.6% annual growth from $20.50.Medical inflation exceeds pricing, commercial and Medicaid pressure persists, OptumHealth stalls, and CRUSH is finalized substantially as proposed with a meaningful UNH recovery and capital burden. FY 2029 adjusted EPS $16, ~−7.9% annually from $20.50.
Financing and share count~8.5% annual adjusted net-income growth plus 1% annual net diluted-share reduction: illustrative 902m denominator to ~875m. Net repurchases are after SBC and issuance; insurer capital and debt reduction take priority.Diluted denominator stays ~902m because reduced buybacks merely offset SBC and issuance. EPS includes interest and modeled regulatory pressure; a forced capital raise or larger recovery is additional downside.
Future valuation19× adjusted diluted EPS13× adjusted diluted EPS
Price in three years$27 × 19 = 513 USD$16 × 13 = 208 USD
Three-year dividends$9.28 annually, no growth: 27.84 USD$9.28 in year one; $4.64 in years two and three: 18.56 USD; 50% cut is analyst stress
Total three-year return+63.7% including dividends−31.4% including dividends

Cash and dilution assumptions: sustaining the base case requires operating cash generation normalized for government-payment timing, after capital expenditure and required insurance capital, to support dividends and net repurchases. The adverse case assumes regulatory recoveries and compliance needs consume cash before shareholder distributions. SBC is an economic cost; the share assumptions are net of issuance. No separate FCF yield, insurance investment balance or excess-cash value is added to this EPS valuation. Interest and modeled regulatory pressure are already included in EPS.

Calculation: (future price + three-year dividends) ÷ 330.48 − 1. Dividends without reinvestment; returns before taxes, fees and FX. No probabilities assigned. Both cases use after-interest diluted EPS; debt, regulatory pressure or dilution is not subtracted again and insurance investments are not added as excess cash.

Present-value check: analyst-assumed 10% required annual return, dividends at year-end: base 408.50 USD, adverse 172.03 USD. Base present-value cushion versus 330.48 is 23.6%. At a 19× terminal multiple and unchanged dividends, FY 2029 EPS of about 21.53 USD is required for that hurdle. These discounted values are separate from the $513/$208 future prices and are not a complete intrinsic-value model.

  • Rationale: the quote fell 18.5% from the November 13 valuation basis, lifting base total return to about +64%. The adverse case was deliberately widened to about −31% because the proposed RADV framework makes a material regulatory outcome more plausible. The improved but still asymmetric risk/reward raises the score from 5.5/10 to 6.7/10.
  • Main weakness: the base requires sustainable $27 EPS and a re-rating to 19×. The adverse case cannot be calibrated precisely because CMS and UNH have not disclosed a company-specific RADV amount; a larger recovery, capital need or prolonged multiple compression could be worse than modeled.
  • Confidence: medium-low. The quote, reported guidance and proposed rule are verified; company-specific RADV exposure, three-year earnings, share count, dividends and multiples are analyst assumptions rather than a complete cash-flow model.
  • Condition for change: near 300 USD or below, with unchanged cases, reconsider toward 7.2/10 (+80.3% / −24.5% including dividends); near 370 USD, toward 6.0/10 (+46.2% / −38.8%); near 400 USD, toward 5.5/10 (+35.2% / −43.4%). A milder final rule, quantified manageable exposure or stronger reserve-neutral margins can raise the score; a large UNH recovery, capital pressure, dilution or lower normalized EPS reduces it. These are review triggers, not trading bands.

Sources for Both Scores

Main current sources: Q3 results and schedules, published October 13, 2026, quarter and nine months ended September 30; Q3 earnings-call transcript, call held October 13; Q3 10-Q, filed November 3, period ended September 30; CMS CRUSH proposed-rule fact sheet, issued November 16 and published in the Federal Register November 19; CMS 2027 Stars, October 8; and Stock Analysis price history, 330.48 USD regular-session close November 19 at 4:00 p.m. EST. Both scores explicitly use methodology 1.2, effective October 16. Reported financials and published rule text are facts; operational explanations and targets are management claims; scenarios and scores are analyst judgments. No current consensus estimate is used.

UNH remains a credible recovery candidate at a more attractive price, with materially higher regulatory uncertainty. Q3 and the 10-Q support the direction of repair; the proposed RADV framework widens the adverse range without yet establishing a UNH-specific loss. Commercial trend above 11%, negative Medicaid margins, reserve contributions, OptumHealth's multi-year target and constrained parent cash prevent treating historical growth as assured. The operating thesis is supported; the risk distribution has worsened.

Research stance: constructive on the direction of recovery; measured on valuation. The share price can work if earnings follow a sustained recovery path. Evidence is not yet sufficient to treat historical margins and growth as automatic.

Next evidence checkpoint: the next reported quarter should test Q4 seasonality, 2027 pricing, commercial and Medicaid margins, reserve-neutral MCR, OptumHealth investment and progress toward leverage targets. Separately monitor the January 19, 2027 CRUSH comment deadline, any final rule, litigation and company-specific RADV disclosure. Next quarterly results: date not searched yet — fewer than two full calendar months have elapsed since the October 13 Q3 release, as required by methodology 1.2.

Evidence confidence: high for published financials, medium for normalized recovery. Valuation readiness: transparent two-case framework, not a full cash-flow model. Key assumptions: October adjusted guidance floor is the starting point; terminal EPS/multiples and dividends are analyst estimates; regulatory outcomes and parent distributable capital remain uncertain.

13

Thesis History / Updates

PeriodDevelopmentImplication
Q2 2025Adjusted full-year EPS outlook reset to at least $16Underwriting and care-delivery problems required a substantial repair
Q3 2025Adjusted EPS $2.92; full-year outlook raised to at least $16.25Early stabilization, with quarterly MCR still 89.9%
FY 2025 resultsAdjusted EPS $16.35; initial 2026 outlook above $17.75A lower earnings base and a measured recovery plan
Q1 2026Adjusted EPS $7.23; 2026 outlook raised above $18.25Pricing and operating actions began to show results
Q2 2026Adjusted EPS $6.38; 2026 outlook raised to $19.50–$20.00Recovery strengthened, while commercial margin repair was delayed
October 9, 2026Initial company Page; Q3 results due October 13Current valuation and thesis tests established before the next report
October 11, 2026Initial methodology 1.0 scores: Business strength 7.2/10; price attractiveness 6/10 at 379.30 USD, October 9 closeExisting recovery thesis formalized; explicit dividends, dilution and discounted scenario checks added
October 13, 2026Q3 release: adjusted EPS $4.69; FY adjusted guidance at least $20.50. Review: strength 7,2/10; attractiveness 6,0/10 at 384.19 USD, Oct 13 pre-market 6:51 a.m. EDT; methodology 1.1Recovery thesis supported, not fundamentally replaced. Scores retained: one further positive quarter is insufficient to remove reserve/pricing risks; current price keeps a limited cushion. Version 1.0 scores remain historical, not retrospectively rescored or strictly like-for-like.
November 13, 2026Post-call and Q3 10-Q review: commercial trend still above 11%; Medicaid margins negative; OptumHealth target path to 2028; Optum Rx retention high 90s. Business strength 7,2/10; price attractiveness 5,5/10 at 405.40 USD, pre-market November 13, 6:44 a.m. EST; methodology 1.2Thesis supported, not fundamentally changed. Company score retained because there is no additional reported quarter; price score reduced as the quote rose and the unchanged base/adverse returns became about +33%/−33%.
November 20, 2026CMS CRUSH proposal reviewed: no FFS adjuster, CMS-set sampling and extrapolation from payment year 2018; industry estimate about $9bn per payment year. Business strength 7.2/10; price attractiveness 6.7/10 at 330.48 USD, November 19 regular close; methodology 1.2Company score retained because the proposal is not final, exposure is unquantified and no new quarter was reported. Price score rose from 5.5 despite a harsher adverse case, as the quote fell 18.5%. Operating-recovery thesis supported; regulatory downside materially higher.

Historical record from the supplied earnings materials. These are business developments, not reconstructed past investment recommendations.

Sources

  • Q3 2026 results and financial schedules: published October 13, 2026; quarter and nine months ended September 30. Q3 Form 10-Q: filed November 3; reserves, cash, debt, shares, legal disclosures and capital. Q3 earnings-call transcript: call held October 13; management commentary on pricing, margins, Stars, OptumHealth and Optum Rx. CMS CRUSH proposed-rule fact sheet: issued November 16; proposed MA RADV mechanics and industrywide recovery estimate. Federal Register proposal: published November 19; formal proposed text and impact analysis.
  • UNH-2Q-2026-transcript.txt: July 16, 2026 earnings call; principal source for operating commentary, guidance, seasonality, capital allocation and management claims.
  • transcript_1Q_2026.txt: April 21, 2026 call; first-half comparisons and earlier guidance.
  • UNH_4Q2025.pdf: FY 2025 earnings call; the $16.35 adjusted EPS baseline, restructuring and initial 2026 outlook.
  • UNH-pressrelease3Q25.pdf: October 28, 2025 release; Q3 performance and outlook.
  • UNH_2Q25_transcript.pdf: July 29, 2025 call; earnings reset and recovery priorities. The supplied UNH_1Q25_transcript.pdf also contains this Q2 call and is not a separate Q1 source.
  • UnitedHealth Q2 2026 results and SEC financial schedules: reported results, GAAP outlook, share denominator and balance sheet.
  • UnitedHealth dividend history: declared quarterly payments.
  • UnitedHealth Q3 release announcement: confirmed October 13 earnings date.
  • CMS 2027 Star Ratings: October 8 release and 2028 quality-bonus timing.
  • Texas attorney general announcement: October 5 investigation announcement; allegations remain unadjudicated.
  • Stock Analysis market quote and history: 330.48 USD regular-session close on November 19, 2026 at 4:00 p.m. EST; November 18 close 349.91 USD and November 13 close 407.46 USD. Historical consensus page: October 8 estimates remain dated background and are not used as current consensus.

Public sources reviewed November 20, 2026. The CMS CRUSH proposal and November 19 market close are incorporated; no additional reported UNH quarter was available. Earlier source files, historical scores and dated consensus remain preserved. Competitive assessments, scores and scenarios are independent analytical judgments; management guidance and targets are not reported future results, and CMS's industrywide estimate is not a UNH-specific liability.


Was this analysis useful to you?

Have a suggestion about this analysis?

Suggestions are not displayed publicly. They help inform future updates. No name or email is required.

Sources and scenarios reflect the date stated in the analysis.Back to all companies